Search Results for “EC” – Page 247 – media

CanSinoBio’s Yu Xuefeng was invited to attend the Asia Healthcare Summit Forum

On May 16, the 4th Asia Healthcare Summit (ASGH), jointly organized by the Hong Kong SAR Government and the Hong Kong Trade Development Council, was held at the Hong Kong Convention and Exhibition Centre. Under the theme of “Innovation – Inclusion – Effectiveness”, the forum covered topics such as challenges and opportunities in the global healthcare industry, the latest developments in medical technology and business opportunities in the Asian healthcare industry, aiming to bring together elites in the global healthcare field to explore ways of innovation and development. Dr. Xuefeng Yu, Chairman and CEO of CanSinoBio, was invited to attend the event to discuss the prospects and business opportunities of the Asian healthcare industry with policy makers, healthcare experts, scholars, business leaders and investors from all over the world, and to strengthen the communication and cooperation among global healthcare industry participants. At the conference, Academician Cao Xuetao, Deputy Director of ...
- Source: drugdu
- 79
- May 21, 2024
Study finds link between malaria parasites developing antimalarial drug resistance

Spread through Anopheles mosquitoes, the disease affected around 249 million people globally in 2022 Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), in collaboration with the Massachusetts Institute of Technology, Columbia University Irving Medical Center and Nanyang Technological University (NTU), Singapore, have identified a link between malaria parasites developing resistance to antimalarial drugs. Affecting around 249 million people globally in 2022, malaria is a mosquito-borne disease that occurs when parasites spread to humans through the bites of infected Anopheles mosquitoes. Specifically focusing on an antimalarial drug known as artemisinin (ART), researchers used a cellular process called transfer ribonucleic acid (tRNA) modification – a mechanism which allows cells to respond rapidly to stress by altering RNA molecules within a cell. ART-based combination therapies are a first-line treatment for patients with uncomplicated malaria and help reduce the number of parasites during the ...
- Source: drugdu
- 73
- May 21, 2024
Liverpool and McMaster University announce £300,000 strategic research partnership

Areas include health research across life stages, from paediatrics to health ageing and resilience The University of Liverpool and McMaster University have announced an institutional strategic partnership, offering £300,000 in seed funding to nine selected projects to support the development of collaborations in key areas of research. The areas of research include health research across life stages, from paediatrics to healthy ageing and resilience, along with social sciences, humanities and research, as well as development in port-related activities. The projects selected were announced by McMaster at a celebratory event with representatives from the University of Liverpool in attendance. The three health research projects selected focus on innovative antibiotic discovery to combat invasive Salmonella in Africa, engineering perfusable vascular organoids for ageing and chronic disease studies and developing pharmacogenetic polygenic risk scores using machine learning methods. David Farrar, president, McMaster, commented: “We’re proud to partner with the University of Liverpool to ...
- Source: drugdu
- 75
- May 21, 2024
Virginia Medicaid Taps Aeroflow Health for Lactation Services

Aeroflow Health, a health tech company, has expanded its lactation consultation services to Virginia Medicaid, it announced Thursday. Asheville, North Carolina-based Aeroflow Health was founded in 2001 and offers an array of medical devices covered by insurance. The company has four lines: Aeroflow Breastpumps, Aeroflow Diabetes, Aeroflow Sleep and Aeroflow Urology. In addition to medical devices, it provides education and consultations. The company has partnerships with more than 1,000 insurance plans. Through Aeroflow’s partnership with Virginia Medicaid and its managed care organizations, new mothers can access breast pumps from Aeroflow. They will also be connected to Aeroflow’s network of lactation consultants. Members can receive one-on-one lactation consultations and online courses that cover topics like breastfeeding, pumping and storing breastmilk. “This partnership between Aeroflow Health and Virginia Medicaid broadens access to lactation services from Aeroflow Breastpumps for new and expecting mothers,” Amanda Minimi, director of corporate development at Aeroflow Health, told ...
- Source: drugdu
- 123
- May 20, 2024
EmpiRx Announces New AI-Powered Platform as Part of Push to Change PBMs

Mike Hollan The platform will use AI technology to provide pharmacists with more tools. The relationship between the pharma industry, pharmacists, and customers continues to evolve. EmpiRx Health, a PBM company headquartered in NJ, announced that it is launching a new AI-powered platform.1 The new platform is called Clinically, and it will use AI technology to help pharmacists with claims adjudication, clinical reviews, and other features that EmpiRx says will put the pharmacists at the center of the PBM model. In a press release, EmpiRx’s CEO Danny Sanchez said, “Our new Clinically platform clearly demonstrates EmpiRx Health’s strong commitment to transforming the pharmacy care industry by creating the PBM of the future – one that’s already providing the highest quality service to customers, patients, and advisor partners. This PBM revolution was long overdue. Far from helping plan sponsors to manage and lower drug costs, the traditional PBM model, which prioritizes ...
- Source: drugdu
- 92
- May 20, 2024
Zydus, MSN partner to license and supply Cabozantinib Tablets for the US

Zydus Lifesciences announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets (a generic version of CABOMETYX) for the US market. As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval. Zydus will exclusively market, distribute, and sell the product in the US market. MSN was the first sole ANDA applicant for Cabozantinib Tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days of generic drug exclusivity for the generic version of CABOMETYX. The total addressable market opportunity of Cabozantinib Tablets in the US is approximately $ 1,464 million. https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-ipsen-enter-exclusive-licensing-agreement
- Source: drugdu
- 115
- May 20, 2024
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop

Ionis and Biogen are halting the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after it failed to show improvement in patients in a Phase I/II study. Data from the 99-patient ALSpire study (NCT04494256) demonstrated that BIIB105 failed to significantly reduce neurodegeneration or improve functional measures such as breathing. BIIB105, an investigational antisense oligonucleotide was designed to reduce the expression of ataxin-2 (ATXN2) protein. Despite demonstrating statistically significant ATXN2 reductions in the study, the drug showed no evidence of clinical benefit in any subgroup evaluated in the study. This marks another setback in the search for new treatments for ALS, a progressive neurodegenerative disease that causes muscle weakness and paralysis. Last month, Amylyx Pharmaceuticals axed its ALS drug Relyvrio (AMX0035) from the market after its Phase III Phoenix trial failed to meet any of its endpoints. However, this trial failure does not mark the end of Ionis and ...
- Source: drugdu
- 103
- May 20, 2024
Roche targets obesity market with early positive trial data

Roche is looking to share in the windfall from the sales in obesity therapies as it announces positive results from the Phase Ib trial of its investigational obesity and type 2 diabetes (T2D) therapy. CT-388 is a once-weekly subcutaneous dual glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist. It selectively targets two incretin receptors that control food intake, energy absorption and assimilation. The therapy has a similar mechanism of action as Eli Lilly’s Mounjaro (tirzepatide), which generated $1.81bn in sales in Q1 this year, according to Lilly’s financials. Following today’s news, the Swiss company’s share was up by over 3.5% in trading today on the Swiss stock market. Roche’s market cap is SFr190.6bn ($210.8bn). The placebo-controlled Phase Ib trial (NCT04838405) enrolled approximately 96 overweight or obese participants with or without T2D. The participants in the CT-388 group achieved a mean placebo-adjusted weight loss of 18.8% at 24 ...
- Source: drugdu
- 106
- May 20, 2024
RUSSIAN HEALTH CARE WEEK 2024

Organiser:ZAO Time:2- 6 Dec. 2024 address：Krasnopresnenskaya naberezhnaya, 14, Moscow, Russia Exhibition hall: Expocentre Exhibition Center Product range: Diagnostic equipment: X-ray diagnostic equipment, ultrasonic diagnostic equipment, functional examination equipment, endoscopy equipment, nuclear medicine equipment, experimental diagnostic equipment, pathological diagnostic equipment, diagnostic imaging equipment, chromatographic analyzer, consulting room analyzer, dialysis and transplant surgery Treatment equipment: clinical radiology equipment; Clinical testing equipment and reagents, ward nursing equipment, surgery equipment, radiotherapy equipment, nuclear medicine treatment equipment, physical and chemical equipment, laser equipment, dialysis treatment equipment, temperature freezing equipment, first aid equipment Auxiliary equipment: disinfection and sterilization equipment, refrigeration equipment, central suction and oxygen supply system, air conditioning equipment, pharmaceutical machinery and equipment, blood bank equipment, medical data processing equipment, medical video and photography equipment, medical air pump system cosmetic equipment; Ophthalmic equipment and treatment technology and materials, dental equipment and instruments, dental repair systems and instruments, oral plastic surgery materials and tools, dental lasers, ...
- Source: drugdu
- 144
- May 20, 2024
Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck

Blackstone Life Sciences startup Uniquity Bio emerged from stealth with an in-licensed drug candidate that could treat a wide range of immunology and inflammation indications. The antibody’s target puts it in competition with drugs from AstraZeneca, Pfizer, and Sanofi.Immunology and inflammation continues to be one of the hottest areas for research, and investment firm Blackstone is joining in with the launch of Uniquity Bio, a new startup whose lead asset from Merck addresses a clinically validated target that puts it in direct competition with some big pharmaceutical companies. Uniquity is backed by up to $300 million in financing from Blackstone Life Sciences, the firm’s biotechnology investment division. The in-licensed Merck drug, solrikitug, is ready to begin Phase 2 development in its lead indications, chronic obstructive pulmonary disease (COPD) and asthma. The Uniquity pipeline includes a third undisclosed gastrointestinal indication. Solrikitug is a monoclonal antibody designed to block thymic stromal lymphoprotein ...
- Source: drugdu
- 74
- May 17, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.